Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in developing adult stem cell therapies for neurodegenerative disorders, such as amyotrophic lateral sclerosis (ALS), Parkinsons disease, and multiple sclerosis. It holds rights to develop and commercialize its NurOwn technology through a worldwide licensing agreement with Ramot, the technology transfer company of the Tel Aviv University.
BCLI's NurOwn technology, an autologous adult stem cell therapy technology that differentiates bone marrow-derived mesenchymal stem cells into specialized neuron-supporting cells. It also has agreements with Hadasit Medical Research Services and Development Ltd. to conduct its ALS clinical trials at the Hadassah Medical Center.
Brainstorm Cell Therapy was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. BCLI was founded in 2000 and is based in New York, New York.
January 23, 2025
RegMed Investors (RMi) Closing Bell: How investors can best navigate the sector ahead
January 22, 2025
RegMed Investors (RMi) Closing Bell: Getting little too frothy
January 17, 2025
RegMed Investors (RMi) Closing Bell: the green on the screen as week closes, thankfully
January 14, 2025
RegMed Investors (RMi) Closing Bell: back in the bag
January 13, 2025
RegMed Investors (RMi) Closing Bell: JPMorgan Healthcare conference kicks-off
January 2, 2025
RegMed Investors (RMi) Closing Bell: first session 2025, cell and gene therapy sector bounced as indexes slumped
December 31, 2024
RegMed Investors (RMi) Closing Bell: lordy, lordy, thanks from above, we’ve had enough
December 23, 2024
RegMed Investors (RMi) Closing Bell: A merry and happy holiday-short week
December 20, 2024
RegMed Investors (RMi) Closing Bell: all cell and gene therapy sector stocks snap to attention
December 19, 2024
RegMed Investors (RMi) Closing Bell: econs are shoving the cell and gene therapy sector
35 companies, 1 interpreter!
Insight, foresight and recommendation
Brainstorm Cell Therapeutics (BCLI) – January '18 openaed at $3.65, dropping in February to $3.45 and continuing to drop to $3.10 on 2/12 and $3.19 on 2/16. Even with their on-going trial, I have a problem with theor corporate transparency ... tey revolve on news and the pricing falls back ...
holdMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2025 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.